We are live on
!
Find out more
BNP Paribas Asset Management Portfolio holdings
AUM
$86.1B
1-Year Est. Return
29.11%
This Fund
S&P 500
This Quarter
Est. Return
-2.17%
1 Year Est. Return
+29.11%
3 Year Est. Return
+87.64%
5 Year Est. Return
+102.48%
10 Year Est. Return
+408.22%
AUM
$86.1B
AUM Growth
-$1.05B
(-1.2%)
Cap. Flow
+$4.86B
Cap. Flow
% of AUM
5.64%
Top 10 Holdings %
Top 10 Hldgs %
27.63%
Holding
2,366
New
101
Increased
1,396
Reduced
686
Closed
108
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$1.43B |
| 2 |
TotalEnergies
TTE
|
+$626M |
| 3 |
Deutsche Bank
DB
|
+$326M |
| 4 |
Stellantis
STLA
|
+$263M |
| 5 |
Broadcom
AVGO
|
+$237M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ciena
CIEN
|
+$291M |
| 2 |
Apple
AAPL
|
+$262M |
| 3 |
Amazon
AMZN
|
+$219M |
| 4 |
Tesla
TSLA
|
+$205M |
| 5 |
Meta Platforms (Facebook)
META
|
+$197M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.22% |
| 2 | Healthcare | 13.97% |
| 3 | Financials | 10.51% |
| 4 | Consumer Discretionary | 10.09% |
| 5 | Industrials | 8.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
876
Celldex Therapeutics
CLDX
$3.07B
| $3.88M | ﹤0.01% |
122,404
-761
| -0.6% | -$20.7K |
|
877
Estee Lauder
EL
$31.5B
| $3.87M | ﹤0.01% |
53,918
+1,813
| +3% | +$185K |
|
878
Ziff Davis
ZD
$2.04B
| $3.83M | ﹤0.01% |
91,218
+335
| +0.4% | +$12.3K |
|
879
Rhythm Pharmaceuticals
RYTM
$7.26B
| $3.82M | ﹤0.01% |
43,872
+41,457
| +1,717% | +$4.03M |
|
880
Valmont Industries
VMI
$9.72B
| $3.8M | ﹤0.01% |
9,522
+7,646
| +408% | +$3.34M |
|
881
HealthEquity
HQY
$8.78B
| $3.77M | ﹤0.01% |
45,171
+8,282
| +22% | +$680K |
|
882
Atmus Filtration Technologies
ATMU
$4.5B
| $3.77M | ﹤0.01% |
66,321
+50,872
| +329% | +$3.01M |
|
883
Vontier
VNT
$4.76B
| $3.74M | ﹤0.01% |
105,579
+731
| +0.7% | +$28.1K |
|
884
MGIC Investment
MTG
$6.35B
| $3.74M | ﹤0.01% |
142,606
-306,148
| -68% | -$8.18M |
|
885
Ocular Therapeutix
OCUL
$1.89B
| $3.74M | ﹤0.01% |
441,775
-3,630
| -0.8% | -$34.6K |
|
886
EXL Service
EXLS
$5.21B
| $3.72M | ﹤0.01% |
122,221
-55,144
| -31% | -$1.9M |
|
887
B2Gold
BTG
$5.18B
| $3.72M | ﹤0.01% |
818,836
+796,880
| +3,629% | +$4M |
|
888
Philip Morris
PM
$291B
| $3.71M | ﹤0.01% |
22,420
-23,222
| -51% | -$4.04M |
|
889
Bausch Health
BHC
$2.41B
| $3.69M | ﹤0.01% |
683,997
+28,942
| +4% | +$173K |
|
890
Haemonetics
HAE
$3.88B
| $3.68M | ﹤0.01% |
65,375
+245
| +0.4% | +$16K |
|
891
Vistra
VST
$48.3B
| $3.64M | ﹤0.01% |
24,193
-6,483
| -21% | -$1.05M |
|
892
Ericsson
ERIC
$33.7B
| $3.62M | ﹤0.01% |
320,911
+92,578
| +41% | +$1M |
|
893
Texas Roadhouse
TXRH
$13.7B
| $3.59M | ﹤0.01% |
21,715
+533
| +3% | +$95.7K |
|
894
RBC Bearings
RBC
$17.9B
| $3.57M | ﹤0.01% |
6,575
-123
| -2% | -$65.3K |
|
895
Dolby
DLB
$5.73B
| $3.52M | ﹤0.01% |
58,682
-5,609
| -9% | -$355K |
|
896
Empire State Realty Trust
ESRT
$852M
| $3.5M | ﹤0.01% |
672,326
-13,582
| -2% | -$81.6K |
|
897
DXC Technology
DXC
$1.76B
| $3.45M | ﹤0.01% |
274,829
-668
| -0.2% | -$8.97K |
|
898
Global Payments
GPN
$24.1B
| $3.45M | ﹤0.01% |
51,301
-27,975
| -35% | -$2.06M |
|
899
HNI Corp
HNI
$3.49B
| $3.45M | ﹤0.01% |
103,185
+87,900
| +575% | +$3.89M |
|
900
LyondellBasell Industries
LYB
$19.7B
| $3.43M | ﹤0.01% |
42,583
-410,700
| -91% | -$24.4M |
|
Similar funds
BNP Paribas Asset Management's Q1 2026 Portfolio in Review
As of Q1 2026, BNP Paribas Asset Management held 2,366 positions worth $86.1B, down 1.2% from $87.2B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
BNP Paribas Asset Management deployed $4.86B of net new capital in Q1 2026, opening 101 new positions and adding to 1,396 existing holdings. Its largest new stake was Viking Holdings: 1,864,036 shares worth $137M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, down from 37% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Ciena, an estimated $291M trimmed.
- BNP Paribas Asset Management's largest Q1 2026 buy was Viking Holdings: 1,864,036 shares worth $137M.
- BNP Paribas Asset Management added most to AstraZeneca in Q1 2026, an estimated $1.43B increase.
- BNP Paribas Asset Management's biggest Q1 2026 reduction was Ciena, cutting an estimated $291M.
- BNP Paribas Asset Management fully exited Exact Sciences in Q1 2026, selling an estimated $35.9M.
- BNP Paribas Asset Management's ten largest holdings make up 28% of its $86.1B portfolio in Q1 2026.
- BNP Paribas Asset Management opened 101 new positions and closed 108 in Q1 2026.
- BNP Paribas Asset Management's portfolio value fell 1.2% quarter-over-quarter to $86.1B.
Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.